- Home
- CKPT vs IKNA Comparison
CKPT vs IKNA Comparison
Compare CKPT & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- IKNA
- Stock Information
- Founded
- CKPT 2014
- IKNA 2016
- Country
- CKPT United States
- IKNA United States
- Employees
- CKPT N/A
- IKNA N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- CKPT Health Care
- IKNA Health Care
- Exchange
- CKPT Nasdaq
- IKNA Nasdaq
- Market Cap
- CKPT N/A
- IKNA 83.0M
- IPO Year
- CKPT 2017
- IKNA 2021
- Fundamental
- Price
- CKPT $3.77
- IKNA $1.68
- Analyst Decision
- CKPT Strong Buy
- IKNA Buy
- Analyst Count
- CKPT 2
- IKNA 2
- Target Price
- CKPT $12.00
- IKNA $3.00
- AVG Volume (30 Days)
- CKPT 946.5K
- IKNA 41.6K
- Earning Date
- CKPT 11-11-2024
- IKNA 11-07-2024
- Dividend Yield
- CKPT N/A
- IKNA N/A
- EPS Growth
- CKPT N/A
- IKNA N/A
- EPS
- CKPT N/A
- IKNA N/A
- Revenue
- CKPT $78,000.00
- IKNA $1,844,000.00
- Revenue This Year
- CKPT N/A
- IKNA N/A
- Revenue Next Year
- CKPT $151,162.55
- IKNA N/A
- P/E Ratio
- CKPT N/A
- IKNA N/A
- Revenue Growth
- CKPT N/A
- IKNA N/A
- 52 Week Low
- CKPT $1.36
- IKNA $1.02
- 52 Week High
- CKPT $3.95
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- CKPT 84.67
- IKNA 51.57
- Support Level
- CKPT $2.37
- IKNA $1.68
- Resistance Level
- CKPT $2.54
- IKNA $1.78
- Average True Range (ATR)
- CKPT 0.27
- IKNA 0.04
- MACD
- CKPT 0.10
- IKNA 0.00
- Stochastic Oscillator
- CKPT 88.60
- IKNA 36.36
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.